Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 18 pharmaceutical deals announced in Q3 2024, worth a total value of $2.9bn. The $1.3bn acquisition of Nerio Therapeutics by Boehringer Ingelheim International was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, immuno-oncology-related deal activity decreased by 69% in Q3 2024 compared with the previous quarter’s total of $9.3bn and rose by 422% as compared to Q3 2023. Related deal volume increased by 50% in Q3 2024 versus the previous quarter and was 100% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in 9M 2024 were Centerview Partners; Lazard; Cantor Fitzgerald with 4, 4, 2 deals respectively.
The top-ranked legal advisors supporting these M&A deals in 9M 2024 were Wilson Sonsini Goodrich & Rosati Professional; Cooley; Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates with 6, 5, 3 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.